# Claritev Corp (CTEV)

Informational only - not investment advice.

CIK: 0001793229
SIC: 7389 Services-Business Services, NEC
SIC breadcrumb: [Services](/division/I/) > [Business Services](/major-group/73/) > [SIC 7389 Services-Business Services, NEC](/industry/7389/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=1793229
Filing source: https://www.sec.gov/Archives/edgar/data/1793229/000179322926000017/ctev-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0001793229-26-000017 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001793229.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 965,413,000 USD | 2025 | verified |
| Net income | -284,282,000 USD | 2025 | verified |
| Assets | 4,888,458,000 USD | 2025 | verified |
| Free cash flow | -12,277,000 USD | 2025 | computed |
| Net margin | -29.45% | 2025 | computed |
| Operating margin | 2.98% | 2025 | computed |
| Revenue YoY | +3.74% | 2025 | computed |

Stockholders' equity was not positive at FY2025 year-end (-173,900,000 USD, as filed); ROE and liabilities / equity are omitted rather than computed.

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only).

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | CTEV | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -29.4% | 5.8% | 3 | 59 |
| Operating margin | 3.0% | 9.2% | 29 | 56 |
| Revenue growth | 3.7% | 8.4% | 30 | 58 |
| FCF margin | -1.3% | 14.2% | 5 | 58 |
| ROA | -5.8% | 2.9% | 17 | 59 |
| Liabilities / equity | 60.30 | 1.52 | 96 | 54 |
| Current ratio | 0.86 | 1.34 | 11 | 57 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 7389 Services-Business Services, NEC, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 965413000 | USD | 2025 | 2026-02-26 |
| Net income | -284282000 | USD | 2025 | 2026-02-26 |
| Assets | 4888458000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001793229.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 1,040,883,000 | 982,901,000 | 937,763,000 | 1,117,602,000 | 1,079,716,000 | 961,524,000 | 930,624,000 | 965,413,000 |
| Net income |  | 36,223,000 | 9,710,000 | -520,564,000 | 102,080,000 | -572,912,000 | -91,697,000 | -1,645,831,000 | -284,282,000 |
| Operating income |  | 427,541,000 | 368,209,000 | -131,821,000 | 386,120,000 | -362,732,000 | 161,982,000 | -1,389,931,000 | 28,765,000 |
| Diluted EPS |  |  | 0.02 | -1.11 | 0.16 | -0.90 | -5.69 | -101.92 | -17.30 |
| Operating cash flow |  | 292,303,000 | 284,313,000 | 377,374,000 | 404,687,000 | 372,364,000 | 171,720,000 | 107,616,000 | 117,324,000 |
| Capital expenditures |  | 63,556,000 | 66,414,000 | 70,813,000 | 84,590,000 | 89,735,000 | 108,852,000 | 118,123,000 | 129,601,000 |
| Share buybacks |  | 0.00 | 0.00 | 101,123,000 | 100,000,000 | 0.00 | 15,218,000 | 10,370,000 | 0.00 |
| Assets |  |  | 8,360,411,000 | 8,283,578,000 | 8,220,407,000 | 7,371,104,000 | 6,964,687,000 | 5,150,827,000 | 4,888,458,000 |
| Liabilities |  |  | 6,375,193,000 | 5,725,713,000 | 5,875,737,000 | 5,580,562,000 | 5,255,563,000 | 5,066,805,000 | 5,055,633,000 |
| Stockholders' equity | 1,949,448,000 | 1,990,388,000 | 1,985,218,000 | 2,557,865,000 | 2,344,670,000 | 1,790,543,000 | 1,709,124,000 | 84,022,000 | -173,900,000 |
| Cash and cash equivalents |  |  | 21,825,000 | 126,755,000 | 185,328,000 | 334,046,000 | 71,547,000 | 16,848,000 | 16,814,000 |
| Free cash flow |  | 228,747,000 | 217,899,000 | 306,561,000 | 320,097,000 | 282,629,000 | 62,868,000 | -10,507,000 | -12,277,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 3.48% | 0.99% | -55.51% | 9.13% | -53.06% | -9.54% |  | -29.45% |
| Operating margin |  | 41.07% | 37.46% | -14.06% | 34.55% | -33.60% | 16.85% | -149.35% | 2.98% |
| Return on assets |  |  | 0.12% | -6.28% | 1.24% | -7.77% | -1.32% | -31.95% | -5.82% |
| Liabilities / equity |  |  | 3.21 | 2.24 | 2.51 | 3.12 | 3.08 | 60.30 |  |
| Current ratio |  |  | 1.35 | 1.86 | 2.25 | 2.54 | 1.16 | 0.82 | 0.86 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-07. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001793229.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 0.03 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.00 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.06 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 242,804,000 | -24,145,000 | -0.04 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 244,135,000 | -31,391,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 234,508,000 | -539,689,000 | -0.83 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 233,476,000 | -576,727,000 | -0.89 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 230,495,000 | -391,450,000 | -24.25 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 232,145,000 | -137,965,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 231,330,000 | -71,319,000 | -4.38 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 241,570,000 | -62,640,000 | -3.81 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 245,959,000 | -69,753,000 | -4.23 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 246,554,000 | -80,570,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 244,678,000 | -73,560,000 | -4.41 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 257,478,000 | -59,226,000 | -3.49 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from CTEV's latest 10-K: [/company/CTEV/business/](/company/CTEV/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from CTEV's latest 10-K: [/company/CTEV/risk-factors/](/company/CTEV/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1793229/000179322926000067/ctev-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-07
Report date: 2026-06-30

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This item and other sections of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created by those sections based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "predicts," "will," "would," "could," "can," "may," and similar terms. Forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of the 2025 Form 10-K and Part II, Item 1A of this Form 10-Q, in each case under the heading “Risk Factors.” Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. We hereby qualify our forward-looking statements by these cautionary statements. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the information included in the Company's 2025 Annual Report on Form 10-K and the condensed consolidated financial statements and accompanying notes included in Part I, Item 1 in this Quarterly Report on Form 10-Q and risks described elsewhere in this Quarterly Report on Form 10-Q and our other filings with the SEC.

Company Overview

Claritev is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality across the healthcare system. We bring objective, market-based insights to some of the healthcare system's most complex decisions based on decades of claims expertise. By applying data, analytics, and experience, we help organizations across the healthcare ecosystem better understand costs, pricing, and payment dynamics. This clarity enables more informed decision-making, reduces friction, and improves how the healthcare system functions in service of greater affordability, alignment, and long-term sustainability.

Although the end beneficiaries of our solutions are employers and other plan sponsors and their health plan members, our direct clients are typically payers, including payers providing administrative services only, and third-party administrators, who go to market with our solutions to those end clients. We offer these payers a single interface to our solutions, which are used in combination or individually to reduce the medical cost burden on their health plan clients by lowering the per-unit cost of medical services incurred, managing the utilization of medical services, and increasing the likelihood that the services are reimbursed without error and accepted by the provider. We are a technology-enabled service provider and transaction processor and do not deliver health-care services, provide or manage healthcare services, provide care or care management, or adjudicate or pay claims.

The Company, primarily through its operating subsidiary, Multiplan, Inc., d/b/a Claritev, offers its solutions nationally through a range of solution lines, which include:

•Claims Intelligence Solutions are designed to reduce medical cost through data-driven algorithms and insights that detect claims over-charges and either negotiate or recommend fair reimbursement for out-of-network medical costs using a variety of data sources and pricing algorithms. Within our claims intelligence solutions, the claim pricing solutions are generally priced based on a percentage of savings achieved. Also included in this category are solutions that enable lower cost health plans that feature reference-based pricing either in conjunction with or in place of a provider network. These solutions are generally priced at a bundled per-employee-per-month ("PEPM") rate;

•Network Solutions are designed to reduce medical cost by providing access to contracted discounts with healthcare providers with whom payers do not have a contractual relationship, through our expansive network of healthcare providers, which forms one of the largest independent preferred provider organizations in the United States. Our network solutions are priced based on either a percentage of savings achieved or at a per employee/member per month fee. This solution category also includes customized network development and management services for payers seeking to expand their network footprint using outsourced services. These solutions are generally priced on a per provider contract or other project-based price;

•Payment and Revenue Integrity Solutions are designed to reduce medical cost through data, technology, and clinical expertise deployed to identify and remove improper and unnecessary charges before or after claims are paid, or to

16

identify and help restore premium dollars underpaid by CMS for government health plans caused by discrepancies with enrollment-related data. Payment and revenue integrity solutions are generally priced based on a percentage of savings achieved; and

•Data and Analytics Solutions are designed to reduce medical costs through a next generation suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that enable clients to optimize decision-making about plan design and network configurations and to support decision-making to improve clinical outcomes, plan performance, and competitive positioning. Data and analytics solutions are generally priced based on a subscription, licensing, or per-member-per month basis. The Company currently reports revenues from data and analytics solutions in claims intelligence solutions and will likely do so until revenues from this solution line become more significant.

We believe our solutions provide a strong value proposition to payers, their health plan customers and healthcare consumers, as well as to providers. Overall, our solution offerings aim to reduce healthcare costs in a manner that is orderly, efficient, and fair to all parties. In addition, because in most instances the fee for our services is linked to the savings we identify, our revenue model is aligned with the interests of our clients.

Results of Operations

The following table provides the results of operations for the periods indicated (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change","","Six Months Ended June 30,","","Change"],["","2026","","2025","","$","","%","","2026","","2025","","$","","%"],["Revenues","$","257,478","","","$","241,570","","","$","15,908","","","6.6","%","","$","502,156","","","$","472,900","","","$","29,256","","","6.2","%"],["Costs of services (exclusive of depreciation and amortization of intangible assets shown below)","67,667","","","60,823","","","6,844","","","11.3","%","","136,747","","","121,259","","","15,488","","","12.8","%"],["General and administrative expenses","55,389","","","51,118","","","4,271","","","8.4","%","","113,219","","","98,086","","","15,133","","","15.4","%"],["Depreciation","24,796","","","25,261","","","(465)","","","(1.8)","%","","49,979","","","49,807","","","172","","","0.3","%"],["Amortization of intangible assets","85,908","","","85,971","","","(63)","","","(0.1)","%","","171,816","","","171,942","","","(126)","","","(0.1)","%"],["Loss on disposal of leases","252","","","1,689","","","(1,437)","","","(85.1)","%","","290","","","5,006","","","(4,716)","","","(94.2)","%"],["Loss on disposal of assets","57","","","130","","","(73)","","","(56.2)","%","","57","","","480","","","(423)","","","(88.1)","%"],["Total expenses","234,069","","","224,992","","","9,077","","","4.0","%","","472,108","","","446,580","","","25,528","","","5.7","%"],["Operating income","23,409","","","16,578","","","6,831","","","41.2","%","","30,048","","","26,320","","","3,728","","","14.2","%"],["Interest expense","100,253","","","99,746","","","507","","","0.5","%","","199,795","","","191,382","","","8,413","","","4.4","%"],["Interest income","(195)","","","(323)","","","128","","","(39.6)","%","","(377)","","","(811)","","","434","","","(53.5)","%"],["Transaction costs related to refinancing transaction","\u2014","","","87","","","(87)","","","(100.0)","%","","\u2014","","","7,879","","","(7,879)","","","(100.0)","%"],["Loss on extinguishment of debt","\u2014","","","\u2014","","","\u2014","","","n/a","","\u2014","","","670","","","(670)","","","(100.0)","%"],["Net loss before taxes","(76,649)","","","(82,932)","","","6,283","","","(7.6)","%","","(169,370)","","","(172,800)","","","3,430","","","(2.0)","%"],["Benefit for income taxes","(17,423)","","","(20,292)","","","2,869","","","(14.1)","%","","(36,584)","","","(38,841)","","","2,257","","","(5.8)","%"],["Net loss","(59,226)","","","(62,640)","","","3,414","","","(5.5)","%","","(132,786)","","","(133,959)","","","1,173","","","(0.9)","%"],["Less: net loss attributable to non-controlling interests","\u2014","","","\u2014","","","\u2014","","","n/a","","\u2014","","","\u2014","","","\u2014","","","n/a"],["Net loss attributable to Claritev Corporation","$","(59,226)","","","$","(62,640)","","","$","3,414","","","(5.5)","%","","$","(132,786)","","","$","(133,959)","","","$","1,173","","","(0.9)","%"]]
[[/GREPCENT_TABLE]]

17

Revenues

The following table presents the total revenue for the periods presented (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change","","Six Months Ended June 30,","","Change"],["","2026","","2025","","$ Change","","% Change","","2026","","2025","","$ Change","","% Change"],["Claims intelligence solutions","$","178,465","","","$","156,966","","","$","21,499","","","13.7","%","","$","344,770","","","$","310,396","","","$","34,374","","","11.1","%"],["Network solutions","50,333","","","54,125","","","(3,792)","","","(7.0)","%","","97,809","","","101,015","","","(3,206)","","","(3.2)","%"],["Payment and revenue integrity solutions","28,680","","","30,479","","","(1,799)","","","(5.9)","%","","59,577","","","61,489","","","(1,912)","","","(3.1)","%"],["Total revenue","$","257,478","","","$","241,570","","","$","15,908","","","6.6","%","","$","502,156","","","$","472,900","","","$","29,256","","","6.2","%"]]
[[/GREPCENT_TABLE]]

Revenues increased by $15.9 million, or 6.6%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. This increase in revenues was due to the increase in Claims intelligence solutions revenues of $21.5 million.

Claims intelligence solutions revenues increased by $21.5 million, or 13.7%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. This increase in revenue was primarily due to an increase in Data iSight and Surprise Bill Services.

Network solutions revenues decreased by $3.8 million, or 7.0%, for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. This decrease in revenue was primarily due to a decrease in the property and casualty market due to non-recurring revenue in the prior period.

Payment and revenue integr

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1793229/000179322926000017/ctev-20251231.htm
Complete FY 2025 MD&A: /company/CTEV/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with Part I, Item 1A. "Risk Factors", our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. For further discussion of our products and solutions, technology and competitive strengths, refer to Item 1. "Business". For discussion related to changes in financial condition and the results of operations for fiscal year 2024 compared to fiscal year 2023, refer to Part II, Item 7. "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for fiscal year 2024, which was filed with the SEC on February 26, 2025.

Company Overview

Claritev is a technology, data and insights company focused on improving transparency, affordability and quality across the healthcare system. We bring objective, market-based insights to some of the healthcare system's most complex decisions based on decades of claims expertise. By applying data, analytics and experience, we help organizations across the healthcare ecosystem better understand costs, pricing and payment dynamics. This clarity enables more informed decision-making, reduces friction, and improves how the healthcare system functions in service of greater affordability, alignment, and long-term sustainability.

Although the end beneficiaries of our solutions are employers and other plan sponsors and their health plan members, our direct clients are typically payers, including payers providing administrative services only, and TPAs, who go to market with our solutions to those end clients. We offer these payers a single interface to our solutions, which are used in combination or individually to reduce the medical cost burden on their health plan clients by lowering the per-unit cost of medical services incurred, managing the utilization of medical services, and increasing the likelihood that the services are reimbursed without error and accepted by the provider. We are a technology-enabled service provider and transaction processor and do not deliver health-care services, provide or manage healthcare services, provide care or care management, or adjudicate or pay claims.

The Company, primarily through its operating subsidiary, Multiplan, Inc., d/b/a Claritev, offers its solutions nationally through a range of solution lines, which include:

•Claims Intelligence Solutions are designed to reduce medical cost through data-driven algorithms and insights that detect claims over-charges and either negotiate or recommend fair reimbursement for out-of-network medical costs using a variety of data sources and pricing algorithms. Within our claims intelligence solutions, the claim pricing solutions are generally priced based on a percentage of savings achieved. Also included in this category are solutions that enable lower cost health plans that feature reference-based pricing either in conjunction with or in place of a provider network. These solutions are generally priced at a bundled PEPM rate;

•Network Solutions are designed to reduce medical cost by providing access to contracted discounts with healthcare providers with whom payers do not have a contractual relationship, through our expansive network of healthcare providers, which forms one of the largest independent preferred provider organizations in the United States. Our network solutions are priced based on either a percentage of savings achieved or at a per employee/member per month fee. This solution category also includes customized network development and management services for payers seeking to expand their network footprint using outsourced services. These solutions are generally priced on a per provider contract or other project-based price;

•Payment and Revenue Integrity Solutions are designed to reduce medical cost through data, technology, and clinical expertise deployed to identify and remove improper and unnecessary charges before or after claims are paid, or to identify and help restore premium dollars underpaid by CMS for government health plans caused by discrepancies with enrollment-related data. Payment and revenue integrity solutions are generally priced based on a percentage of savings achieved; and

•Data and Analytics Solutions are designed to reduce medical costs through a next generation suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that enable clients to optimize decision-making about plan design and network configurations and to support decision-making to improve clinical outcomes, plan performance, and competitive positioning. Data and analytics solutions are generally priced based on a subscription, licensing, or per-member-per month basis. The Company currently reports revenues from data and analytics solutions in claims intelligence solutions and will likely do so until revenues from this solution line become more significant.

In 2025, the Company advanced its long-term growth strategy by initiating its first international market expansion into the Middle East and North Africa ("MENA") region starting with a strategic partnership with Claims Care Revenue Cycle Management LLC ("Claims Care"), a division of Burjeel Holdings. We signed additional revenue-generating opportunities with other healthcare organizations and are expanding our partnerships and alliances to build and deliver state-of-the-art solutions, tailored to the needs of the MENA market and beyond.

45

Table of Contents

We believe our solutions provide a strong value proposition to payers, their health plan clients and healthcare consumers, as well as to providers. Overall, our solution offerings aim to reduce healthcare costs in a manner that is orderly, efficient, and fair to all parties. In addition, because in most instances the fee for our solutions is linked to the savings we identify, we believe our revenue model is aligned with the interests of our clients.

We group our claims charges into two categories that correspond to differing characteristics of identified savings performance:

•Commercial Health Plans. This category primarily represents our claims intelligence solutions and network solutions claims. These claims are pre-payment in nature, generate savings through repricing, and are characterized by a higher percentage of potential medical cost savings as a percentage of medical charges processed. For the year ended December 31, 2025, this category represented approximately 84.5% of our revenues. Solutions included in this category are as follows:

◦Claims Intelligence Solutions

▪Reference-Based Pricing

▪Negotiation Services

▪Surprise Billing Services

◦Network Solutions

▪Primary Networks

▪Complementary Networks

▪Government Networks

▪Network Management Services

◦Payment and Revenue Integrity Solutions

▪Clinical Negotiation

•Payment & Revenue Integrity Solutions, Property & Casualty, and Other. This category includes claims that typically generate savings at a lower percentage of charge volumes or that are processed on a per-claim or flat fee basis (rather than a percentage of savings basis), as well as other network solutions. These claims are both pre-payment and post-payment in nature. For the year ended December 31, 2025, this category represented approximately 15.5% of our revenues. Solutions included in this category are as follows:

◦Payment and Revenue Integrity Solutions

▪Pre-Payment Integrity

▪Coordination of Benefits

▪Subrogation

▪Data Mining

▪Revenue Integrity

◦Network Solutions

▪Property & Casualty Network Services (pre-payment)

▪Other network services

The following table presents the medical charges processed and the potential savings identified across our products and revenue streams, including PEPM and percentage of savings ("PSAV"), for the periods presented (in billions):

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","2023"],["Commercial Health Plans"],["Medical charges processed","$","86.5","","$","80.2","","$","75.1"],["Potential medical cost savings","$","23.2","","$","23.2","","$","21.7"],["Potential savings as % of charges","26.8%","","28.9%","","28.9%"],["Payment & Revenue Integrity, Property & Casualty, and Other"],["Medical charges processed","$","93.3","","$","97.4","","$","93.6"],["Potential medical cost savings","$","1.8","","$","1.4","","$","1.3"],["Potential savings as % of charges","1.9%","","1.4%","","1.4%"],["Total"],["Medical charges processed","$","179.8","","$","177.6","","$","168.7"]]
[[/GREPCENT_TABLE]]

46

Table of Contents

[[GREPCENT_TABLE]]
[["Potential medical cost savings","$","25.0","","$","24.6","","$","23.0"],["Potential savings as % of charges","13.9%","","13.9%","","13.6%"]]
[[/GREPCENT_TABLE]]

Medical charges processed represent the aggregate dollar amount of claims processed by our cost management and payment and revenue integrity solutions in the period presented. Not all medical charges processed will generate savings, therefore revenues. The dollar amount of the claim for the purposes of this calculation is the dollar amount of the claim prior to any reductions that may be made as a result of the claim being processed by our solutions.

Potential medical cost savings represent the aggregate amount of potential savings in dollars identified by our cost management and payment and revenue integrity solutions in the period presented. Since certain of our fees are based on the amount of savings achieved by our clients, and our clients are the final adjudicator of the claims and may choose not to reduce claims or reduce claims by only a portion of the potential savings identified, potential medical cost savings may not directly correlate with the amount of fees earned in connection with the processing of such claims.

Reverse Stock Split

On September 20, 2024, the Company effected a one-for-forty (1-for-40) reverse stock split of its Class A common stock (the "Reverse Stock Split").

References to Class A common stock, warrants to purchase Class A common stock, options to purchase Class A common stock, restricted stock units, share data, per share data and conversion rates with respect to convertible notes and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Non-GAAP Financial Measures

We use EBITDA, Adjusted EBITDA and Adjusted Earnings Per Share ("Adjusted EPS") to evaluate our financial performance. EBITDA, Adjusted EBITDA and Adjusted EPS are financial measures that are not presented in accordance with GAAP. We believe the presentation of these non-GAAP financial measures provides useful information to investors in assessing our financial condition and results of operations across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our financial operating results of our core business.

These measurements of financial performance have important limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Additionally, they may not be comparable to other similarly titled measures of other companies. Some of these limitations are:

•such measures do not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments;

•such measures do not reflect changes in, or cash requirements for, our working capital needs;

•such measures do not reflect the significant interest expense, or cash requirements necessary to service interest or principal payments on our debt;

•such measures do not reflect any cash requirements for any future replacement of depreciated assets;

•such measures do not reflect the impact of stock-based compensat

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/CTEV/mda/fy2025/
All MD&A years: /company/CTEV/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/CTEV/mda/fy2024/): filed 2025-02-26; accession 0001793229-25-000022 (https://www.sec.gov/Archives/edgar/data/1793229/000179322925000022/mpln-20241231.htm)
- [FY 2023 MD&A](/company/CTEV/mda/fy2023/): filed 2024-02-29; accession 0001793229-24-000012 (https://www.sec.gov/Archives/edgar/data/1793229/000179322924000012/mpln-20231231.htm)
- [FY 2022 MD&A](/company/CTEV/mda/fy2022/): filed 2023-03-01; accession 0001793229-23-000013 (https://www.sec.gov/Archives/edgar/data/1793229/000179322923000013/mpln-20221231.htm)
- [FY 2021 MD&A](/company/CTEV/mda/fy2021/): filed 2022-02-25; accession 0001793229-22-000021 (https://www.sec.gov/Archives/edgar/data/1793229/000179322922000021/mpln-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 7389 Services-Business Services, NEC) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/CTEV.md · JSON record: /company/CTEV.json · verified financials: /company/CTEV/financials.json / /company/CTEV/financials.csv · machine TOC for the whole site: /llms.txt